Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus K TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus K TAB.
K-LEASE vs K-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Renal (90% unchanged), fecal (10% as metabolites)
Category C
Category C
Potassium Supplement
Potassium Supplement